HETLIOZ (TASIMELTEON) CAPSULES
Live / Registered — Registered and renewed (as of 30 Jun 2025)
What this means for you
Registered since 16 Jun 2015. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 16 Jun 2025).
Record
- Serial number
- 86185566
- Registration number
- 4756956
- Mark type
- Design + words
- Filed
- 05 Feb 2014
- Published for opposition
- 13 Jan 2015
- Registered
- 16 Jun 2015
- Next maintenance due
- 16 Jun 2025
- Attorney of record
- Jayme M. Torelli
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, containing tasimelteon, for use in the treatment of diseases and disorders of the central nervous system, diseases and disorders having an impact on the central nervous system, and diseases and disorders having a central nervous system manifestation
Owner
- Vanda Pharmaceuticals Inc., Washington, DC, US
- Vanda Pharmaceuticals Inc., Washington, DC, US
- Vanda Pharmaceuticals Inc., Washington, DC, US
Prior registrations
Prosecution history
- 30 Jun 2025 — NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
- 30 Jun 2025 — REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
- 30 Jun 2025 — REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
- 30 Jun 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 23 Jan 2025 — TEAS SECTION 8 & 9 RECEIVED
- 16 Jun 2024 — COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
- 04 Sept 2020 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 04 Sept 2020 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 02 Sept 2020 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 16 Jun 2020 — TEAS SECTION 8 & 15 RECEIVED
- 16 Jun 2020 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 16 Jun 2015 — REGISTERED-PRINCIPAL REGISTER
- 13 May 2015 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 12 May 2015 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 22 Apr 2015 — STATEMENT OF USE PROCESSING COMPLETE